|
1
|
Wong ND: Epidemiological studies of CHD
and the evolution of preventive cardiology. Nat Rev Cardiol.
11:276–289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Libby P and Theroux P: Pathophysiology of
coronary artery disease. Circulation. 111:3481–3488. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ridker PM and Lüscher TF:
Anti-inflammatory therapies for cardiovascular disease. Eur Heart
J. 35:1782–1791. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boisvert WA: The participation of
inflammatory cells in atherosclerosis. Drugs Today (Barc).
37:173–179. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Libby P: Inflammation in atherosclerosis.
Arterioscler Thromb Vasc Biol. 32:2045–2051. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seneviratne AN and Monaco C: Role of
inflammatory cells and toll-like receptors in atherosclerosis. Curr
Vasc Pharmacol. 13:146–160. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chistiakov DA, Orekhov AN and Bobryshev
YV: Immune- inflammatory responses in atherosclerosis: Role of an
adaptive immunity mainly driven by T and B cells. Immunobiology.
221:1014–1033. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Martinet W, Schrijvers DM and De Meyer GR:
Molecular and cellular mechanisms of macrophage survival in
atherosclerosis. Basic Res Cardiol. 107:2972012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bruunsgaard H, Skinhøj P, Pedersen AN,
Schroll M and Pedersen BK: Ageing, tumour necrosis factor-alpha
(TNF-alpha) and atherosclerosis. Clin Exp Immunol. 121:255–260.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Popa C, Netea MG, van Riel PL, van der
Meer JW and Stalenhoef AF: The role of TNF-alpha in chronic
inflammatory conditions, intermediary metabolism, and
cardiovascular risk. J Lipid Res. 48:751–762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sbarsi I, Falcone C, Boiocchi C, Campo I,
Zorzetto M, De Silvestri A and Cuccia M: Inflammation and
atherosclerosis: The role of TNF and TNF receptors polymorphisms in
coronary artery disease. Int J Immunopathol Pharmacol. 20:145–154.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang H, Park Y, Wu J, Chen XP, Lee S,
Yang J, Dellsperger KC and Zhang C: Role of TNF-alpha in vascular
dysfunction. Clin Sci (Lond). 116:219–230. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iida S and Komiyama N: Balance between
interleukin-1beta and interleukin-1 receptor antagonist in the
development of atherosclerosis. A polymorphism in the interleukin-1
receptor antagonist. Circ J. 73:1401–1402. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin SJ, Yen HT, Chen YH, Ku HH, Lin FY and
Chen YL: Expression of interleukin-1 beta and interleukin-1
receptor antagonist in oxLDL-treated human aortic smooth muscle
cells and in the neointima of cholesterol-fed endothelia-denuded
rabbits. J Cell Biochem. 88:836–847. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Legendre F, Bogdanowicz P, Boumediene K
and Pujol JP: Role of interleukin 6 (IL-6)/IL-6R-induced signal
tranducers and activators of transcription and mitogen-activated
protein kinase/extracellular. J Rheumatol. 32:1307–1316.
2005.PubMed/NCBI
|
|
16
|
Biasucci LM, Liuzzo G, Fantuzzi G,
Caligiuri G, Rebuzzi AG, Ginnetti F, Dinarello CA and Maseri A:
Increasing levels of interleukin (IL)-1Ra and IL-6 during the first
2 days of hospitalization in unstable angina are associated with
increased risk of in-hospital coronary events. Circulation.
99:2079–2084. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kotla S, Singh NK, Heckle MR, Tigyi GJ and
Rao GN: The transcription factor CREB enhances interleukin-17A
production and inflammation in a mouse model of atherosclerosis.
Sci Signal. 6:ra832013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Usui F, Kimura H, Ohshiro T, Tatsumi K,
Kawashima A, Nishiyama A, Iwakura Y, Ishibashi S and Takahashi M:
Interleukin-17 deficiency reduced vascular inflammation and
development of atherosclerosis in Western diet-induced
apoE-deficient mice. Biochem Biophys Res Commun. 420:72–77. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu F, Wang Q, Guo C, Wang X, Cao X, Shi
Y, Gao F, Ma C and Zhang L: IL-17 induces apoptosis of vascular
endothelial cells: A potential mechanism for human acute coronary
syndrome. Clin Immunol. 141:152–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ye L, Ji L, Wen Z, Zhou Y, Hu D, Li Y, Yu
T, Chen B, Zhang J, Ding L, et al: IL-37 inhibits the production of
inflammatory cytokines in peripheral blood mononuclear cells of
patients with systemic lupus erythematosus: Its correlation with
disease activity. J Transl Med. 12:692014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boraschi D, Lucchesi D, Hainzl S, Leitner
M, Maier E, Mangelberger D, Oostingh GJ, Pfaller T, Pixner C,
Posselt G, et al: IL-37: A new anti-inflammatory cytokine of the
IL-1 family. Eur Cytokine Netw. 22:127–147. 2011.PubMed/NCBI
|
|
22
|
Nold MF, Nold-Petry CA, Zepp JA, Palmer
BE, Bufler P and Dinarello CA: IL-37 is a fundamental inhibitor of
innate immunity. Nat Immunol. 11:1014–1022. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu K, Min X, Lin Y, Huang Y, Huang S, Liu
L, Peng Y, Meng K, Li D, Ji Q and Zeng Q: Increased IL-37
concentrations in patients with arterial calcification. Clin Chim
Acta. 461:19–24. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Zhai Y, Ao L, Hui H, Fullerton DA,
Dinarello CA and Meng X: Interleukin-37 suppresses the inflammatory
response to protect cardiac function in old endotoxemic mice.
Cytokine. 95:55–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nomenclature and criteria for diagnosis of
ischemic heart disease. Report of the Joint International Society
and Federation of Cardiology/World Health Organization task force
on standardization of clinical nomenclature. Circulation.
59:607–609. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen B, Huang K, Ye L, Li Y, Zhang J,
Zhang J, Fan X, Liu X, Li L, Sun J, et al: Interleukin-37 is
increased in ankylosing spondylitis patients and associated with
disease activity. J Transl Med. 13:362015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Imaeda H, Takahashi K, Fujimoto T, Kasumi
E, Ban H, Bamba S, Sonoda H, Shimizu T, Fujiyama Y and Andoh A:
Epithelial expression of interleukin-37b in inflammatory bowel
disease. Clin Exp Immunol. 172:410–416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao PW, Jiang WG, Wang L, Jiang ZY, Shan
YX and Jiang YF: Plasma levels of IL-37 and correlation with
TNF-alpha, IL-17A, and disease activity during DMARD treatment of
rheumatoid arthritis. PLoS One. 9:e953462014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ballak DB, van Diepen JA, Moschen AR,
Jansen HJ, Hijmans A, Groenhof GJ, Leenders F, Bufler P,
Boekschoten MV, Müller M, et al: IL-37 protects against
obesity-induced inflammation and insulin resistance. Nat Commun.
5:47112014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moschen AR, Molnar C, Enrich B, Geiger S,
Ebenbichler CF and Tilg H: Adipose and liver expression of
interleukin (IL)-1 family members in morbid obesity and effects of
weight loss. Mol Med. 17:840–845. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sakai N, Van Sweringen HL, Belizaire RM,
Quillin RC, Schuster R, Blanchard J, Burns JM, Tevar AD, Edwards MJ
and Lentsch AB: Interleukin-37 reduces liver inflammatory injury
via effects on hepatocytes and non-parenchymal cells. J
Gastroenterol Hepatol. 27:1609–1616. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chai M, Zhang HT, Zhou YJ, Ji QW, Yang Q,
Liu YY, Zhao YX, Shi DM, Liu W, Yang LX, et al: Elevated IL-37
levels in the plasma of patients with severe coronary artery
calcification. J Geriatr Cardiol. 14:285–291. 2017.PubMed/NCBI
|
|
34
|
Li Y, Wang Z, Yu T, Chen B, Zhang J, Huang
K and Huang Z: Increased expression of IL-37 in patients with
Graves' disease and its contribution to suppression of
proinflammatory cytokines production in peripheral blood
mononuclear cells. PLoS One. 9:e1071832014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Swirski FK and Nahrendorf M: Leukocyte
behavior in atherosclerosis, myocardial infarction, and heart
failure. Science. 339:161–166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu B, Meng K, Ji Q, Cheng M, Yu K, Zhao X,
Tony H, Liu Y, Zhou Y, Chang C, et al: Interleukin-37 ameliorates
myocardial ischaemia/reperfusion injury in mice. Clin Exp Immunol.
176:438–451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Visvanathan S, Wagner C, Marini JC, Baker
D, Gathany T, Han J, van der Heijde D and Braun J: Inflammatory
biomarkers, disease activity and spinal disease measures in
patients with ankylosing spondylitis after treatment with
infliximab. Ann Rheum Dis. 67:511–517. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zaba LC, Cardinale I, Gilleaudeau P,
Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duculan J, Novitskaya
I, Khatcherian A, Bluth MJ, Lowes MA and Krueger JG: Amelioration
of epidermal hyperplasia by TNF inhibition is associated with
reduced Th17 responses. J Exp Med. 204:3183–3194. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang Y, Zhang ZX, Lian D, Haig A,
Bhattacharjee RN and Jevnikar AM: IL-37 inhibits IL-18-induced
tubular epithelial cell expression of pro-inflammatory cytokines
and renal ischemia-reperfusion injury. Kidney Int. 87:396–408.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McNamee EN, Masterson JC, Jedlicka P,
McManus M, Grenz A, Collins CB, Nold MF, Nold-Petry C, Bufler P,
Dinarello CA and Rivera-Nieves J: Interleukin 37 expression
protects mice from colitis. Proc Natl Acad Sci USA.
108:16711–16716. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Katta S, Karnewar S, Panuganti D, Jerald
MK, Sastry BKS and Kotamraju S: Mitochondria-targeted esculetin
inhibits PAI-1 levels by modulating STAT3 activation and miR-19b
via SIRT3: Role in acute coronary artery syndrome. J Cell Physiol.
233:214–225. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zheng Y, Wang Z, Deng L, Zhang G, Yuan X,
Huang L, Xu W and Shen L: Modulation of STAT3 and STAT5 activity
rectifies the imbalance of Th17 and Treg cells in patients with
acute coronary syndrome. Clin Immunol. 157:65–77. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tete S, Tripodi D, Rosati M, Conti F,
Maccauro G, Saggini A, Cianchetti E, Caraffa A, Antinolfi P,
Toniato E, et al: IL-37 (IL-1F7) the newest anti-inflammatory
cytokine which suppresses immune responses and inflammation. Int J
Immunopathol Pharmacol. 25:31–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Akdis M, Burgler S, Crameri R, Eiwegger T,
Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, et
al: Interleukins, from 1 to 37, and interferon-γ: Receptors,
functions, and roles in diseases. J Allergy Clin Immunol.
127:701–721.e1-e70. 2011. View Article : Google Scholar : PubMed/NCBI
|
